An online GLP-1 prescription, from first click to follow-up

What does a GLP-1 prescription cover?

The gut releases a chemical messenger called GLP-1 that helps regulate appetite and blood sugar. Semaglutide imitates that signal.

These medicines are peptides: short strings of amino acids, the small units proteins are built from. The long ingredient name and the brand name tell you different things. Ask for both, plus the form of the medicine.

FDA is short for the U.S. Food and Drug Administration. An approval applies to a specific medicine and use.

Which ingredient am I reading about?

What can a study tell me?

The average loss in STEP 1 at week 68 was 14.9% on semaglutide and 2.4% on the dummy treatment. Participants had obesity, or overweight with another weight-related condition, and no diabetes. The trial included lifestyle support and was funded by Novo Nordisk; an average cannot predict an individual result.

SURMOUNT-1 followed adults without diabetes for 72 weeks: average loss with tirzepatide ranged from 15.0% to 20.9%, depending on the trial group, against 3.1% with a dummy treatment. Eli Lilly supported that trial, which included regular visits and lifestyle support. Those are separate studies, not a direct contest between treatments.

How does online prescribing work?

A useful starting point is a conversation about your health, rather than a request for a particular box.

Where can I seek care?

Both a telehealth assessment and a visit to an in-person practice are routes to consider. A physician’s license or other state authorization has to cover the place you are sitting during the visit. That is the state-based approach described by federal guidance and medical-board policy in the September 26, 2026 check.

For an online visit, make a short list of your questions and current medicines. Keep the exact product names handy, including anything from another service. Tell the clinician what you hope care will help with, and what worries you about starting.

From first click to follow-up

1. Choose the care

   Get the clinician and pharmacy names. Read the regular fee and cancellation terms.

2. Have an assessment

   Discuss your health and questions. Ask what still needs a test or an in-person visit.

3. Agree on follow-up

   Keep the contact route and review plan. Ask how a concern gets to a clinician.

This is a path to discuss with the service, not a promised timetable. Before sharing payment details, find out whether a declined prescription changes the charge.

Is a form enough on its own?

The Federation of State Medical Boards describes two ways to assess someone remotely. You may talk with a doctor live, or send health information for the doctor to read later. Both ways must meet the proper standard of care. That means the level of care expected for the same issue in person. The group’s May 2026 guidance says a website cannot replace a medical assessment with a list of medicines for you to choose from. People also need a channel for asking their own follow-up questions. This is guidance for boards, not a single nationwide prescribing law, as checked September 26, 2026.

Under the medical-board policy, needed tests or an exam must be completed, arranged or referred to another professional. Ask who organizes that next step and who explains the result.

How can I check the care?

Start with names that can be checked outside the sales page.

Can I check the clinician and pharmacy?

Physician license records and public discipline actions are held by state medical boards. A doctor of osteopathic medicine uses the letters DO; a medical doctor uses MD. Both are doctors, but some states license them through separate boards. Ask the service which letters to look for in the directory. That record reports public actions; it cannot tell you how well a visit will go.

The Federation of State Medical Boards gathers physician-board links in its contact directory. FDA’s state-by-state pharmacy links lead to pharmacy license records. Use the names provided by the service, not just the name across the top of its website.

Open the physician-board directory
Open FDA’s pharmacy search links

FDA lists a valid prescription, a U.S. physical address and phone number, access to a licensed pharmacist and state pharmacy licensing as signs to check. It also cautions that unsafe websites can imitate real pharmacy storefronts.

Is a compounded product the same thing?

A pharmacy or doctor can prepare a medicine for a particular need through a process called compounding. The resulting preparation does not receive FDA approval. Its effectiveness, manufacturing quality and safety are not verified by the agency before marketing. As of September 26, 2026, FDA still treated compounded preparations as medicines without its approval.

How do shortage rules affect the offer?

During the national shortages, pharmacies could make their own versions of semaglutide and tirzepatide injections under the shortage rules. Neither injection was on FDA’s shortage list on September 26, 2026, so that permission had ended.

For a named person, a regular compounding pharmacy can make a changed version when the prescriber judges the difference from the available medicine to be significant for that person. The change must be in the medicine itself; a discount does not qualify. The law otherwise limits regular copying. Ask which unmet need the preparation addresses, and how the approved options fall short.

Liraglutide injections were still on FDA’s shortage list when checked November 3, 2026. A separate FDA proposal concerned places that compound in batches, called outsourcing facilities. FDA proposed leaving liraglutide off the allowed-ingredient list for those batch-making facilities. Here liraglutide means the starting drug ingredient used to prepare a medicine, rather than a finished product. The proposal had not become a final determination by September 26, 2026. This is a reason to ask about the exact product, not assume that every online offer has the same footing.

Which claims call for a pause?

• FDA flags offers without screening and a prescription, as well as the lack of a clinician to answer questions after delivery.
• Calling a compounded medicine an FDA-approved generic is misleading under FDA guidance checked September 26, 2026.
• FDA records checked November 3, 2026 still showed no semaglutide or tirzepatide generic approved for U.S. sale.
• A research-only label is another concern: FDA cautions against these products for human treatment, citing uncertain quality and potential harm.

What needs a safety check?

Bring the health details a form may not have asked about.

The labels make family thyroid-cancer history, previous pancreas or gallbladder illness and severe stomach conditions relevant to the assessment. Pregnancy plans, medicines for diabetes and planned operations also belong in that discussion. Tirzepatide labels also raise questions about birth control pills, while semaglutide and tirzepatide labels flag existing diabetic eye disease.

What side effects are common?

Nausea, diarrhea, vomiting and constipation appear in the weight-management labels for semaglutide, tirzepatide and liraglutide. Severe vomiting or diarrhea can lead to fluid loss and kidney injury; the labels carry warnings about this.

Ask who to contact if you feel unwell and how to get a reply outside a planned review. Keep that answer somewhere easy to find, rather than inside an old message thread.

What does the thyroid warning mean?

The labels checked September 26, 2026 carry a boxed warning, the strongest label warning, about thyroid tumors observed in rats or mice. Whether these medicines cause those tumors in humans is unknown.

Medullary thyroid cancer is the rare type named in these labels. These medicines are ruled out for someone with a personal or family history of that cancer. If the family diagnosis is unclear, ask for the medical record and discuss it with the prescriber.

The labels also exclude a rare inherited condition: multiple endocrine neoplasia type 2, usually called MEN 2. In this condition, tumors develop in glands that make hormones. If that diagnosis appears in your family history, ask the prescriber to review it. A prior serious allergic reaction to the particular medicine or its ingredients also rules it out.

What if pregnancy or surgery is planned?

Pregnancy wording differs by product, so a shared rule for all these medicines would be misleading. For planned pregnancy, the Wegovy label gives prescribers a minimum two-month gap after stopping semaglutide. The Zepbound and Saxenda labels instead direct stopping once pregnancy is recognized. Bring pregnancy and breastfeeding questions to the clinician who knows the exact product.

The labels warn that stomach contents may reach the lungs when a procedure involves medicines that make someone unconscious or deeply sleepy. The semaglutide label asks people to tell the surgical team they take it. There is not enough evidence to know whether stopping before surgery lowers that risk. Ask the surgical team for a plan.

What happens after the first prescription?

Agree on how the next conversation will happen before the first visit ends.

Ask when progress will be reviewed, who can change the plan and what happens if the medicine cannot be obtained. Keep the full product name with your contact details for the service. A portal is the service’s website or app where you send messages about your care. If it shows only a general inbox, ask who reads your message and who can answer medicine questions.

What will be reviewed?

The Wegovy and Saxenda labels include checks on blood sugar for people with diabetes, resting heart rate and kidney function when fluid loss is a concern. Ask which checks apply to the particular medicine and health history, where they happen and who explains them.

What if I want to stop?

The STEP 1 extension followed people after the original trial of semaglutide ended. The group regained roughly two-thirds of its lost weight in the year after stopping semaglutide. Weight regain also occurred after a switch off tirzepatide in SURMOUNT-4. These findings make a conversation about the longer plan useful. They do not decide how long any one person will use a medicine.

Ask what a pause, a change or an end to treatment would involve. Include cost in that conversation if it could interrupt care. The next step needs to make sense beyond the first discounted month.

Words in plain English

Match an unfamiliar word to the question it helps you ask.

Active ingredient

The ingredient that has the medicine’s intended effect; ask for this name as well as the brand.

Compounding

Making a preparation to suit a particular need instead of supplying the finished factory product.

Formulary

A plan’s covered-drug list; the entry for the precise product matters more than a general drug-family name.

Generic

A version of a brand-name drug that received its own FDA approval as a copy. Compounding does not give a medicine this approval.

GLP-1

A hormone released by the gut that helps regulate appetite and blood sugar.

Prior authorization

An insurer’s review before it agrees to pay; a prescription by itself does not settle coverage.

Telehealth

A health visit with the participants in different places, using remote communication.